| Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data FC Bidard, DJ Peeters, T Fehm, F Nolé, R Gisbert-Criado, D Mavroudis, ... The lancet oncology 15 (4), 406-414, 2014 | 920 | 2014 |
| Broad targeting of angiogenesis for cancer prevention and therapy Z Wang, C Dabrosin, X Yin, MM Fuster, A Arreola, WK Rathmell, ... Seminars in cancer biology 35, S224-S243, 2015 | 512 | 2015 |
| Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function NS Patel, JL Li, D Generali, R Poulsom, DW Cranston, AL Harris Cancer research 65 (19), 8690-8697, 2005 | 482 | 2005 |
| Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2–positive operable breast cancer: results of the randomized phase II … V Guarneri, A Frassoldati, A Bottini, K Cagossi, G Bisagni, S Sarti, ... Journal of clinical oncology 30 (16), 1989-1995, 2012 | 434 | 2012 |
| Epithelial–mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact C Foroni, M Broggini, D Generali, G Damia Cancer treatment reviews 38 (6), 689-697, 2012 | 355 | 2012 |
| Hypoxia-inducible factor-1α expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer D Generali, A Berruti, MP Brizzi, L Campo, S Bonardi, S Wigfield, ... Clinical Cancer Research 12 (15), 4562-4568, 2006 | 330 | 2006 |
| The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib M Milani, T Rzymski, HR Mellor, L Pike, A Bottini, D Generali, AL Harris Cancer research 69 (10), 4415-4423, 2009 | 323 | 2009 |
| Designing a broad-spectrum integrative approach for cancer prevention and treatment KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ... Seminars in cancer biology 35, S276-S304, 2015 | 302 | 2015 |
| Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis FC Bidard, S Michiels, S Riethdorf, V Mueller, LJ Esserman, A Lucci, ... JNCI: Journal of the National Cancer Institute 110 (6), 560-567, 2018 | 261 | 2018 |
| Breast tumour angiogenesis SB Fox, DG Generali, AL Harris Breast cancer research 9, 1-11, 2007 | 249 | 2007 |
| The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper M Cristofanilli, JY Pierga, J Reuben, A Rademaker, AA Davis, DJ Peeters, ... Critical reviews in oncology/hematology 134, 39-45, 2019 | 242 | 2019 |
| Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients A Bottini, D Generali, MP Brizzi, SB Fox, A Bersiga, S Bonardi, G Allevi, ... Journal of Clinical Oncology 24, 3623-3628, 2006 | 229 | 2006 |
| Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 SR Oakes, F Vaillant, E Lim, L Lee, K Breslin, F Feleppa, S Deb, ... Proceedings of the National Academy of Sciences 109 (8), 2766-2771, 2012 | 221 | 2012 |
| Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients D Generali, G Bates, A Berruti, MP Brizzi, L Campo, S Bonardi, A Bersiga, ... Clinical Cancer Research 15 (3), 1046-1051, 2009 | 180 | 2009 |
| Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta … M Giuliano, F Schettini, C Rognoni, M Milani, G Jerusalem, T Bachelot, ... The Lancet Oncology 20 (10), 1360-1369, 2019 | 174 | 2019 |
| Clinical portrait of the SARS-CoV-2 epidemic in European patients with cancer DJ Pinato, A Zambelli, J Aguilar-Company, M Bower, CCT Sng, R Salazar, ... Cancer discovery 10 (10), 1465-1474, 2020 | 167 | 2020 |
| Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer G Roviello, A Ravelli, K Polom, R Petrioli, L Marano, D Marrelli, F Roviello, ... Cancer letters 372 (2), 187-191, 2016 | 162 | 2016 |
| Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma A Berruti, P Sperone, A Ferrero, A Germano, A Ardito, AM Priola, ... European journal of endocrinology 166 (3), 451-458, 2012 | 161 | 2012 |
| Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer D Generali, FM Buffa, A Berruti, MP Brizzi, L Campo, S Bonardi, A Bersiga, ... Journal of Clinical Oncology 27 (2), 227-234, 2009 | 150 | 2009 |
| Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial NJ Robert, MN Saleh, D Paul, D Generali, L Gressot, MS Copur, ... Clinical breast cancer 11 (2), 82-92, 2011 | 148 | 2011 |
